Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | FLT1 | P17948 | 1/20 | 0.50 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1953578 | 0.92 | POLB (0.61) | POLBHTTL3MBTL1NPC1CYP3A4 | |
| SCHEMBL8902175 | 0.90 | CHEK1 (0.51) | POLBHTTL3MBTL1CYP3A4PDGFRB | |
| SCHEMBL31305210 | 0.88 | PDGFRB (0.51) | POLBHTTL3MBTL1NPC1CYP3A4 | |
| SCHEMBL18700346 | 0.87 | PDGFRB (0.51) | POLBHTTL3MBTL1NPC1CYP3A4 | |
| SCHEMBL29734700 | 0.87 | POLB (0.50) | POLBHTTL3MBTL1NPC1CYP3A4 | |
| SCHEMBL5256629 | 0.87 | POLB (0.50) | POLBHTTL3MBTL1NPC1CYP3A4 | |
| SCHEMBL30837492 | 0.87 | PDGFRB (0.55) | POLBHTTPDGFRBFGFR1PDGFRA | |
| SCHEMBL12108924 | 0.87 | PDGFRB (0.55) | POLBHTTPDGFRBFGFR1PDGFRA | |
| SCHEMBL31430540 | 0.87 | PDGFRB (0.48) | POLBHTTL3MBTL1NPC1CYP3A4 | |
| SCHEMBL1721368 | 0.86 | PDGFRB (0.47) | POLBHTTL3MBTL1NPC1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116648250-B | Novel quinazoline derivatives as SOS1 inhibitors and uses thereof | 韩美药品株式会社 | 2025-06-13 | — | — | CN | disclosed |
| US-20240067613-A1 | NOVEL QUINAZOLINE DERIVATIVES AS SOS1 INHIBITORS AND USE THEREOF | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2024-02-29 | — | — | US | disclosed |
| US-20240067613-A1 | NOVEL QUINAZOLINE DERIVATIVES AS SOS1 INHIBITORS AND USE THEREOF | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2024-02-29 | — | — | US | disclosed |
| US-20240067613-A1 | NOVEL QUINAZOLINE DERIVATIVES AS SOS1 INHIBITORS AND USE THEREOF | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2024-02-29 | — | — | US | disclosed |
| EP-4269395-A1 | NOVEL QUINAZOLINE DERIVATIVE COMPOUND AS SOS1 INHIBITOR, AND USE THEREOF | Hanmi Pharmaceutical Co., Ltd. (KR) | 2023-11-01 | — | — | EP | disclosed |
| EP-4269395-A1 | NOVEL QUINAZOLINE DERIVATIVE COMPOUND AS SOS1 INHIBITOR, AND USE THEREOF | Hanmi Pharmaceutical Co., Ltd. (KR) | 2023-11-01 | — | — | EP | disclosed |
| CN-116648250-A | Novel quinazoline derivatives as SOS1 inhibitors and uses thereof | 韩美药品株式会社 | 2023-08-25 | — | — | CN | disclosed |
| WO-2022139304-A1 | NOVEL QUINAZOLINE DERIVATIVE COMPOUND AS SOS1 INHIBITOR, AND USE THEREOF | 한미약품 주식회사 | 2022-06-30 | — | — | WO | disclosed |
| US-20100298324-A1 | Prolyl Hydroxylase Inhibitors | SMITH KLINE BEECHAM CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298324-A1 | Prolyl Hydroxylase Inhibitors | SMITH KLINE BEECHAM CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298324-A1 | Prolyl Hydroxylase Inhibitors | SMITH KLINE BEECHAM CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2240178-A1 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2010059549-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059549-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2009086044-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITH KLINE BEECHAM CORPORATION (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086044-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITH KLINE BEECHAM CORPORATION (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298324-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | POLB 1480/4885HTT 1882/4885L3MBTL1 2188/4885 |
| US-20240067613-A1 | NOVEL QUINAZOLINE DERIVATIVES AS SOS1 INHIBITORS AND USE THEREOF | SOS1, RASGRP1, RAC1 | POLB 4751/4885HTT 4706/4885L3MBTL1 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.